Abstract 1520P
Background
The NAPOLI 3 trial reported a survival benefit with the combination therapy nanoliposomal Irinotecan, 5-Fluorouracil, Leucovorin and Oxaliplatin (NALIRIFOX) versus nabPaclitaxel and Gemcitabine in first line therapy for metastatic pancreatic ductal Adenocarcinoma (mPDAC). In this study we aim to analyze the efficacy and feasibility of this promising new first line regime in an early real-world setting.
Methods
The analyzed population included patients with unresectable or metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX at 3 Austrian cancer centers. The primary endpoint of the study was overall survival (OS), while secondary endpoints included progression free survival (PFS), overall response rate (ORR), and safety. All patient data including molecular profiles were obtained by individual chart review.
Results
From February 2023 to April 2024, 40 patients were enrolled. After a median follow up of 7.9 months (95% CI 6.44-10.36), median PFS was 5.3 months (95% CI 3.45-6.71), and median OS was 12.7 months (95% CI 8.94-NR). The investigator assessed confirmed ORR was 63% and the disease control rate was 78%. Any grade adverse events (AEs) occurred in 40 patients (100%). Grade 3-4 AEs occurred in 17 patients (42.50%). The most common side effects were hypokalemia (53.13%) and diarrhea (52.5%). Among hypokalemia cases, 82% experienced severe (G3/G4) adverse events, while for diarrhea, the percentage of severe AEs was 19%. In 9 patients (22.50%) treatment-emergent adverse events leading to discontinuation. No treatment-related treatment-emergent adverse events leading to death were detected. KRAS was present in 87.5%.
Conclusions
To the best of our knowledge this is the first real-world analysis of NALIRIFOX in pancreatic cancer. Efficacy results confirm the phase NAPOLI 3 trial while holding promising safety.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Reichinger.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18